Highlights Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
1.36 ^USD	+3.82%		+13.33%	+29.52%

Mar. 19	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
Feb. 27	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M	Feb. 27	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : Stock Futures -2-	Jan. 23	DJ
North American Morning Briefing : Stock Futures -2-	Jan. 12	DJ
Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis	Jan. 10	CI
Sun Pharmaceutical Signs Licensing Pact with Aclaris Therapeutics	Dec. 05	MT
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia	Dec. 05	CI
Aclaris Therapeutics to stop development of rheumatoid arthritis drug	Nov. 13	RE
Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update	Nov. 13	CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q3 Revenue $9.3M	Nov. 06	MT
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)	23-10-03	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q2 Revenue $1.9M	23-08-07	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Aclaris Therapeutics Q1 Loss Widens, Revenue Increases; Shares Down Pre-Bell	23-05-08	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q1 Revenue $2.5M, vs. Street Est of $1.8M	23-05-08	MT
Aclaris shares tank as skin disorder drug fails mid-stage study	23-03-06	RE
Aclaris Therapeutics, Inc. Announces Preliminary Topline Data from 12-Week Phase 2A Study of Oral Zunsemetinib (Ati-450) for Moderate to Severe Hidradenitis Suppurativa	23-03-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Highlights

Filters